BTIG lowered the firm’s price target on Cryoport (CYRX) to $10 from $13 and keeps a Buy rating on the shares following the firm’s survey of biopharma manufacturers. R&D Services budgets will likely face the most risk and headwinds over the next 2 years, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYRX:
- CryoPort Sells CRYOPDP Business to DHL Group
- CryoPort Holds 2025 Annual Stockholders Meeting
- Cryoport Inc’s Earnings Call Highlights Growth and Partnerships
- CryoPort’s Strong Performance and Growth Potential Justifies Buy Rating Despite Macroeconomic Challenges
- Cryoport Reports Strong Start to 2025 with Revenue Growth